1. Scrip
  2. >>Leadership
  3. >>Interviews

Fosun Pharma’s Global R&D Head On Original Innovation In China

 
• By Dexter Jie Yan

Original innovation in drug development is vital for Chinese pharmas to grow into international majors within a decade, while originality is not necessarily restricted to the first-in-class category, Xingli Wang, head of Fosun Pharma’s Global R&D, shares his thoughts with Scrip.

Xingli Wang
Xingli Wang, CEO of the Global R&D Center of Shanghai Fosun Pharmaceutical (Group) (Fosun Pharma)

For Chinese pharma companies, betting even a sliver of their total research and development spendings on original innovation can make a difference.

That very difference may determine whether they can grow into an international major in the timeframe of a decade, Xingli Wang, CEO of the Global R&D Center of Shanghai Fosun...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Interviews

More from Scrip

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.